Vault-13

TCG Crossover Management, LLC

PALO ALTO, CA · CIK 1839948 · 13F filing filed 2022-08-15

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$235.4m reported value -5.5% vs Q1 2022
22positions
80.2%in top 10
2 new 4 added 4 reduced 0 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 COGENT BIOSCIENCES INC COM COGT COGT 3,481,042 $31.4m13.34% 13.34% AddedShares held: Q3 2021 —, Q4 2021 2.8m, Q1 2022 3.0m, Q2 2022 3.5m +500.0k +500,000 16.8%
2 IVERIC BIO INC COM OPHT OPHT 2,914,250 $28.0m11.91% 11.91% AddedShares held: Q3 2021 —, Q4 2021 1.7m, Q1 2022 2.5m, Q2 2022 2.9m +397.3k +397,330 15.8%
3 GERON CORP COM GERN GERN 15,096,342 $23.4m9.94% 9.94% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 14.3m, Q2 2022 15.1m +810.6k +810,627 5.7%
4 KURA ONCOLOGY INC COM KURA KURA 1,167,642 $21.4m9.09% 9.09% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 506.4k, Q2 2022 1.2m +661.2k +661,219 130.6%
5 CYMABAY THERAPEUTICS INC COM CBAY CBAY 5,905,400 $17.4m7.40% 7.40% UnchangedShares held: Q3 2021 —, Q4 2021 5.9m, Q1 2022 5.9m, Q2 2022 5.9m
6 ACLARIS THERAPEUTICS INC COM ACRS ACRS 1,144,939 $16.0m6.79% 6.79% UnchangedShares held: Q3 2021 —, Q4 2021 1.1m, Q1 2022 1.1m, Q2 2022 1.1m
7 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 1,314,000 $15.2m6.46% 6.46% UnchangedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 1.3m, Q2 2022 1.3m
8 CHINOOK THERAPEUTICS INC COM ADRO ADRO 796,460 $13.9m5.92% 5.92% ReducedShares held: Q3 2021 —, Q4 2021 882.4k, Q1 2022 882.4k, Q2 2022 796.5k -85.9k -85,893 -9.7%
9 AEROVATE THERAPEUTICS INC COM COM 889,572 $13.9m5.91% 5.91% UnchangedShares held: Q3 2021 —, Q4 2021 853.3k, Q1 2022 889.6k, Q2 2022 889.6k
10 ENTRADA THERAPEUTICS INC COM TRDA TRDA 663,694 $8.1m3.43% 3.43% UnchangedShares held: Q3 2021 —, Q4 2021 663.7k, Q1 2022 663.7k, Q2 2022 663.7k
11 MERUS N V COM MRUS MRUS 300,000 $6.8m2.89% 2.89% UnchangedShares held: Q3 2021 —, Q4 2021 225.0k, Q1 2022 300.0k, Q2 2022 300.0k
12 TYRA BIOSCIENCES INC COM TYRA TYRA 896,418 $6.4m2.72% 2.72% UnchangedShares held: Q3 2021 —, Q4 2021 850.5k, Q1 2022 896.4k, Q2 2022 896.4k
13 AKOUOS INC COM COM 1,350,006 $6.3m2.69% 2.69% UnchangedShares held: Q3 2021 —, Q4 2021 1.0m, Q1 2022 1.4m, Q2 2022 1.4m
14 TANGO THERAPEUTICS INC COM TNGX TNGX 1,172,250 $5.3m2.26% 2.26% ReducedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 1.3m, Q2 2022 1.2m -82.2k -82,250 -6.6%
15 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD MLTX MLTX 1,000,000 $5.2m2.23% 2.23% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 1.0m
16 ALPINE IMMUNE SCIENCES INC COM NVLS NVLS 578,260 $4.9m2.09% 2.09% ReducedShares held: Q3 2021 —, Q4 2021 1.2m, Q1 2022 1.0m, Q2 2022 578.3k -456.0k -455,962 -44.1%
17 89BIO INC COM ETNB ETNB 1,133,196 $3.6m1.55% 1.55% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 1.1m
18 ZAI LAB LTD ADR ZLAB ZLAB 95,000 $3.3m1.40% 1.40% UnchangedShares held: Q3 2021 —, Q4 2021 95.0k, Q1 2022 95.0k, Q2 2022 95.0k
19 MAGENTA THERAPEUTICS INC COM COM 2,124,122 $2.5m1.08% 1.08% UnchangedShares held: Q3 2021 —, Q4 2021 2.2m, Q1 2022 2.1m, Q2 2022 2.1m
20 ANAPTYSBIO INC COM ANAB ANAB 58,515 $1.2m0.50% 0.50% UnchangedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 58.5k, Q2 2022 58.5k
21 ELEVATION ONCOLOGY INC COM COM 555,000 $777.0k0.33% 0.33% UnchangedShares held: Q3 2021 —, Q4 2021 555.0k, Q1 2022 555.0k, Q2 2022 555.0k
22 PARDES BIOSCIENCES INC COM COM 59,039 $181.0k0.08% 0.08% ReducedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 229.1k, Q2 2022 59.0k -170.1k -170,061 -74.2%